Semiconductor design software provider Cadence Design Systems (NASDAQ:CDNS) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 26.9% year on year to $1.36 billion. On the other hand, the company’s full-year revenue guidance of $5.18 billion at the midpoint came in 1.3% below analysts’ estimates. Its non-GAAP profit of $1.88 per share was 3.2% above analysts’ consensus estimates.
(Bloomberg) -- Analysts’ forecasts for Japanese stocks show little correlation with their actual performance, according to an analysis of 20 years of data from a former chief strategist at Nomura Holdings Inc. who now teaches at a university in Tokyo.Most Read from BloombergWhy Barcelona Bought the Building That Symbolizes Its Housing CrisisPor qué Barcelona compró el edificio que simboliza su crisis inmobiliariaTrump Child Refugee Agency Shares Data With Immigration EnforcersA Filmmaker’s Surre
Conagra Brands trimmed its sales and earnings outlook for the fiscal year, citing challenges sourcing chicken and frozen vegetables.
Walgreens shares jumped Tuesday after a report the pharmacy chain's possible deal to sell itself to private equity firm Sycamore Partners may be back on the table.
Elon Musk's controversial role in the Trump administration appears to be dragging down the Tesla CEO's image — and brand — during a pivotal time for the EV industry.
Shares of beer, wine, and spirits company Constellation Brands (NYSE:STZ) jumped 8.7% in the pre-market session after Warren Buffett's Berkshire Hathaway revealed a position in the company (STZ) worth roughly $1.2 billion in the fourth quarter of 2024. Given Buffett's reputation for identifying quality opportunities in the stock market, the market is likely to read the information positively for the company's prospects in the near term.
Shares of pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA) jumped 13.5% in the morning session after CNBC's David Faber said that a potential deal between the company (Walgreens) and private equity firm Sycamore Partners "was showing signs of life." The stock's reaction is lifting investors' optimism as markets continue to digest the long-term implications of its recent dividend suspension (first time in over 90 years) and lawsuit with the Department of Justice.
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results. Despite this, Barclays seems to be exercising caution, downgrading the stock to equal weight from overweight earlier in the morning. The firm cited "policy risks, fewer clinical catalysts, and broader economic uncertainties that could limit its upside.".
Shares of packaged foods company Conagra Brands (NYSE:CAG) fell 7.7% in the morning session after the company reported underwhelming preliminary full-year 2025 guidance and expects sales and profits to be below its previous forecast. Precisely, the company expects full-year earnings of about $2.35 (vs. previous guidance of $2.45 to $2.50 per share). Organic sales are also expected to decline by 2% year on year (vs previous guidance of a decline between 1.5% and flat growth).
British government borrowing costs surged and then eased in January as investors tried to price global inflation risks in the light of Trump's plan for tariffs on trade partners. "It is what's coming out of Washington on tariffs that is moving that term premium around, day by day and hour by hour," Bailey said, referring to the extra interest investors demand for holding longer-dated debt.